Article Text

PDF
Additional response to the correspondence: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Cantini and Bennuci
  1. Marc Scherlinger1,
  2. Thierry Schaeverbeke2
  1. 1Service de Rhumatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
  2. 2Université de Bordeaux, Bordeaux, France
  1. Correspondence to Dr Marc Scherlinger, Service de Rhumatologie, Centre Hospitalier Universitaire de Bordeaux, 33000 Bordeaux, France; marc.scherlinger{at}chu-bordeaux.fr

Statistics from Altmetric.com

We read with great interest Cantini and Benucci’s response to our letter.1 However, we would like to add some points to the debate.

To date and to our knowledge, every single clinical trial investigating efficacy and safety of biosimilars in rheumatology using a double-blinded design has failed to report any clinical difference with the original biologic. The double-blinded controlled trial NOR-SWITCH as well as open-label extension studies such as PLANETRA investigating efficacy and safety of the switch from original to biosimilar infliximab also failed to report any difference.2 3 These studies unequivocally condone the grade 1b recommendation 6 regarding the efficacy and safety of the switch published …

View Full Text

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.